ArticleBlood advances2025
Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL.
John N Allan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it
ArticleBlood advances2025
John N Allan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.